Natural Polymeric Materials based Drug Delivery Systems in Lung Diseases (PDF)

external grant funding and his work has involved interdisciplinary collaborations across many clinical, practice and project design areas. Jon has authored over 580 peer-reviewed academic publications and is Chief Editor of 8 international research books and author of over 70 book chapters. Jon is the only Australian researcher ever to have attracted 3 consecutive Government Fellowships (NHMRC and ARC) focused upon complementary and integrative health care and he was recently awarded a prestigious Fulbright Senior Scholarship (2019) to examine complementary and integrative medicine for vulnerable communities in Boston, US. Jon holds leadership roles at both the Public Health Association of Australia (PHAA) and the American Public Health Association (APHA) and his research has been commissioned by and/or partnered with the World Health Organization (WHO) and various Ministries of Health.Prof Raimar Löbenberg holds a BS in pharmacy from the Johannes Gutenberg-University in Mainz, Germany. He received his PhD in Pharmaceutics from the Johann Wolfgang Goethe-University in Frankfurt in 1996 for his work in drug delivery using nanoparticles. He joined the University of Alberta in the year 2000. His research interests are in Biopharmaceutics to predict the oral performance of drugs and botanicals and inhalable nanoparticles to treat lung diseases like lung cancer, tuberculosis or leishmaniasis. He is founder and director of the Drug Development and Innovation Centre at the University of Alberta. He was president of the Canadian Society for Pharmaceutical Sciences 2014-2015. He is the member of the United States Pharmacopeia Dietary Supplement Expert Committee. He is vice chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science. He is member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology. Dr Lobenberg is also the member of the Health Canada Scientific Advisory Committee on Opiate Abuse.Dr. Andreoli Pintös educational background is in Pharmaceutical Sciences (Bachelor, Master's and Ph.D.). Her career is more than 40 years of sound experience in Academia, being currently Full Professor in one of the most prestigious Universities in Brazil: University of São Paulo. Dr. Andreoli Pinto develops and run researches on Dosage Forms, focusing on Parenterals (formulation, analytical, microbiological and performance methods) and Medical Devices. Under her supervision, out of 50 researchers concluded their scientific investigations and she has authored 180 articles in scientific journals, over 12 book chapters. She also has two commercial patents to her name and have taken the management roles in the University, such as being Dean of School of Pharmacy for two mandates (2004-2008 and 2012-2016) and also being Chair of Deliberative Board of FURP - a pharmaceutical industry that manufactures products from the WHO Essential Medicines List and is run by Sao Paulo State Government. Strong scientific skills allied to leadership and management allowed her to establish agreements with internationally prestigious institutions (Universities of Alberta, Lisbon and Bath) as well as some important national scientific and educational institutions.Dr Kamal Dua, Senior Lecturer, Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney (UTS), has a research experience of over 12 years working in the field of drug delivery targeting inflammatory diseases. Dr Dua is also a Node Leader of Drug Delivery Research in the Centre for Inflammation at Centenary Institute/UTS and Senior Research Fellow, the Australian Research Centre in Complementary and Integrative Medicine (ARCCIM), where the targets identified from the research projects are pursued to develop novel formulations as the first step towards translation into clinics. Dr Dua researches in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one another helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua's research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of inflammation in chronic airway diseases and cancer.